Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3D-959 for Mild-to-Moderate Alzheimer's Disease
NCT06964230Phase 3Not yet recruiting
- Sponsor
- T3D Therapeutics
- Start
- Oct 2026
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing T3D-959 30mg with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 at 78 weeks and Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living at 78 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
t3d-959
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06964230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964230.